Application 761325

Type
BLA
Sponsor
SANOFI-AVENTIS U.S. LLC

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761325Meriloginsulin aspart-szjj351(k) BiosimilarRx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001MERILOGINSULIN ASPART-SZJJINJECTION;SOLUTION10ML(100UNITS/ML)NoNo
002MERILOG SOLOSTARINSULIN ASPART-SZJJINJECTION;SOLUTION3ML(100UNITS/ML)NoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 ยท 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MERILOGINSULIN ASPART-SZJJSanofi-Aventis U.S. LLCeee07a52-1102-4d48-9782-26061db175ad2025-10-07Warnings, Adverse reactionsExact identifier
application number: BLA761325

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
82309ORIG 2025-05-27
81259ORIG 2025-02-14
81255ORIG 2025-02-14